Chris Mitchell

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 480 citations · Full text

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

Anthony V. Moorman, Hannah Ensor, Sue Richards et al. · The Lancet Oncology · 2010 · 388 citations

Hematological Malignancy, Lymphoid Neoplasia, Pediatric Hematology +7

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 301 citations · Full text

Hematological Malignancy, Post-remission Therapy, Young People +13

Outcome for children and young people with <scp>E</scp>arly <scp>T</scp>‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, <scp>UKALL</scp> 2003

Katharine Patrick, Rachel Wade, Nick Goulden et al. · British Journal of Haematology · 2014 · 229 citations

Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial

Ajay Vora, Chris Mitchell, Lynne Lennard et al. · The Lancet · 2006 · 186 citations

Hematological Malignancy, Oncology, Pediatric Hematology +9